Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + pembrolizumab is a combination regimen consisting of cabozantinib, a multi-targeted tyrosine kinase inhibitor, and pembrolizumab, an anti–PD-1 monoclonal antibody immune checkpoint inhibitor. Cabozantinib targets multiple tyrosine kinases, including MET, VEGFR-2, RET, AXL, and FLT-3, inhibiting tumor angiogenesis, cell proliferation, and metastasis, and modulating the tumor microenvironment. Pembrolizumab blocks the PD-1 receptor on T-cells, thereby restoring antitumor immune response. Their use in combination is under investigation and has shown promising antitumor activity and manageable safety in several cancer types, including metastatic renal cell carcinoma, ICI-resistant gastroesophageal adenocarcinoma, and advanced sarcomas[1][2][3][4][5][7].
- Brand names
- KeytrudaCabometyxCometriq
- Other names
- pembrolizumab + cabozantinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TEK (Tie2)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on cabozantinib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + pembrolizumab.